Business Wire

GSMA

27.2.2020 09:32:12 CET | Business Wire | Press release

Share
GSMA: ICT Industry Agrees Landmark Science-based Pathway to Reach Net Zero Emissions

The ICT industry is today taking an unprecedented step forward in tackling climate change with the release of the first-ever science-based pathway to reduce Greenhouse Gas (GHG) emissions across the telecoms sector. This supports the GSMA’s commitment to helping the mobile industry achieve Net Zero carbon emissions by 2050.

The new Science-Based Target (SBT) is the result of a collaboration between the ITU, GeSI, the GSMA, and SBTi to develop a sector-specific decarbonisation pathway that allows ICT companies to set targets in line with the latest climate science. It includes emissions reductions trajectories for mobile, fixed and data centre operators to meet the ambitious Paris Agreement goal of limiting global warming to 1.5°c, designed to substantially reduce the risks and effects of climate change.

Twenty nine operator groups representing 30 per cent of global mobile connections are already committed to SBTs. These include America Movil, AT&T, BT, Bharti Airtel, Deutsche Telekom, Elisa, Far Eastone, KPN, Magyar Telekom, NTT DOCOMO, Orange, Proximus, Reliance Jio Infocomm, Safaricom, Singtel, SK Telecom, STC, Swisscom, T Mobile USA, Taiwan Mobile, TDC, Tele2, Telefónica, Telekom Austria, Telenor, Telia, Telstra, Verizon, and Vodafone.

Many more will now be able to set targets by applying the trajectory recommendations released today.

“Today’s landmark agreement underlines how the ICT sector is taking urgent and unprecedented action in response to the climate emergency,” said Mats Granryd, Director General, GSMA. “The mobile industry is one of the first major sectors in the world to voluntarily set an SBT for emissions reductions. Our sector will form the backbone to the future global economy and has a unique role to play in reaching a Net Zero economy. A decarbonised world will be a digital world, so we must show leadership and take responsibility for driving positive climate action.”

The GSMA is also launching a Climate Toolkit for operators today which includes company guidance for setting science-based targets. Further information is available at: https://www.gsma.com/betterfuture/climate-action-toolkit

Renewable energy to drive emissions reductions

The SBT sets emissions trajectory reductions over the decade (2020-2030) for each ICT sub- sector. For example, mobile network operators adopting the SBT are required to reduce emissions by at least 45 per cent over this period. Companies are required to set one target for their combined Scope 1 and 2 emissions, with additional guidance provided for managing Scope 3 emissions1 .

The switch to renewable and low-carbon electricity is expected to account for the bulk of reductions over this period, alongside efforts by operators to become more energy efficient. Access to renewable energy, which can vary widely depending on an operator’s geographic location is, therefore, a key factor determining an operator’s ability to meet the SBT.

The ICT sector pathway SBT was approved by the Science-Based Target Initiative (SBTi) this month following a consultation period. Full details are provided in the official ITU standard: GHG emissions trajectories for the ICT sector compatible with the UNFCCC Paris Agreement (Ref: Recommendation ITU L.1470).

Mobile industry demonstrating leadership on climate action

Today’s announcement forms part of the GSMA’s climate action roadmap for the mobile industry, which has already seen operators disclose their climate impacts, energy, and emissions via the internationally recognised CDP global disclosure system.2

The GSMA is working with participating operators and partnering with the international community, climate experts and third-party organisations to advance industry progress, establish best practices, and support disclosure and target setting. The work forms part of the industry’s journey to support the delivery of the UN’s Sustainable Development Goals (SDGs), specifically SDG #13 on Climate Action.

The industry is also committed to advancing mobile technology innovations in areas such as big data and IoT that can enable energy efficient and environmental solutions across multiple sectors, including transport, manufacturing, agriculture, building, and energy. A recent report produced by the GSMA and the Carbon Trust calculated that the use of mobile technology enabled a global reduction in emissions of around 2,135 million tonnes CO2 e in 20183 . These emissions savings were almost ten times greater than the global carbon footprint of the mobile industry itself.

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA

1 https://www.epa.gov/greeningepa/greenhouse-gases-epa

2 https://www.gsma.com/newsroom/press-release/worlds-leading-mobile-operators-to-disclose-climate-impacts-as-part-of-new-gsma-led-climate-action-roadmap/

3 https://www.gsma.com/newsroom/press-release/mobile-technologies-enabling-huge-carbon-reductions-in-response-to-climate-emergency/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye